New antibody drug targets tough lung cancer in early trial

NCT ID NCT07423585

Recruiting now Disease control Sponsor: Asrar Alahmadi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This Phase 2 trial tests tarlatamab, a bispecific antibody that helps immune cells attack cancer cells, in 39 patients with extensive-stage small-cell lung cancer. The goal is to see if it can delay cancer growth and improve survival. Participants will receive tarlatamab and undergo biopsies and scans to monitor their response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tarlatamab
What this could lead to: If successful, tarlatamab could offer a new treatment option that delays cancer growth and extends survival for people with extensive-stage small-cell lung cancer.
What could go wrong: This is an early Phase 2 trial with only 39 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the cancer, requiring patients to switch to standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.